Almog T, Lazar S, Reiss N et al (2008) Identification of extracellular signal-regulated kinase 1/2 and p38 MAPK as regulators of human sperm motility and acrosome reaction and as predictors of poor spermatozoan quality
We cant recommend or direct you to those sources, but we can help you understand the risks and explore safer, legal alternatives
Carrier peptides GHK-Cu differs as it is a Matrixial carrier peptide
While it is not a standalone cancer treatment, its ability to support immune competence has made it an area of significant scientific interest
What sets GHK-Cu apart is Its multifunctional nature and its ability to work at the cellular level, not the surface level like other treatments
Beyond bloodwork, documenting baseline measurements and tracking progress through photos and subjective notes every two to four weeks gives you concrete evidence of whether the protocol is working as intended